[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1057864A1 - Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders. - Google Patents

Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders.

Info

Publication number
HK1057864A1
HK1057864A1 HK04100730A HK04100730A HK1057864A1 HK 1057864 A1 HK1057864 A1 HK 1057864A1 HK 04100730 A HK04100730 A HK 04100730A HK 04100730 A HK04100730 A HK 04100730A HK 1057864 A1 HK1057864 A1 HK 1057864A1
Authority
HK
Hong Kong
Prior art keywords
cns
disorders
preparation
nervous system
central nervous
Prior art date
Application number
HK04100730A
Other languages
English (en)
Inventor
Wayne Everett Childers
Michael Gerard Kelly
Sharon Joy Rosenzweig-Lipson
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of HK1057864A1 publication Critical patent/HK1057864A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK04100730A 2000-11-28 2004-02-04 Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders. HK1057864A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25330100P 2000-11-28 2000-11-28
US29781401P 2001-06-13 2001-06-13
PCT/US2001/043160 WO2002044142A2 (en) 2000-11-28 2001-11-27 Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders

Publications (1)

Publication Number Publication Date
HK1057864A1 true HK1057864A1 (en) 2004-04-23

Family

ID=26943115

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04100730A HK1057864A1 (en) 2000-11-28 2004-02-04 Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders.

Country Status (25)

Country Link
US (3) US6469007B2 (hu)
EP (1) EP1339406B1 (hu)
JP (1) JP4198989B2 (hu)
KR (1) KR100835552B1 (hu)
CN (1) CN100352437C (hu)
AR (1) AR035603A1 (hu)
AT (1) ATE269078T1 (hu)
AU (2) AU2002237654B2 (hu)
BR (1) BR0115609A (hu)
CA (1) CA2428039C (hu)
DE (1) DE60103927T2 (hu)
DK (1) DK1339406T3 (hu)
EA (1) EA005925B1 (hu)
ES (1) ES2222401T3 (hu)
HK (1) HK1057864A1 (hu)
HU (1) HUP0400551A2 (hu)
IL (1) IL156098A0 (hu)
MX (1) MXPA03004677A (hu)
NO (1) NO325501B1 (hu)
NZ (1) NZ526150A (hu)
PL (1) PL363219A1 (hu)
PT (1) PT1339406E (hu)
TR (1) TR200401546T4 (hu)
TW (1) TWI224102B (hu)
WO (1) WO2002044142A2 (hu)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432826B1 (en) * 1999-11-29 2002-08-13 Applied Materials, Inc. Planarized Cu cleaning for reduced defects
US20060287335A1 (en) * 2000-11-28 2006-12-21 Wyeth Serotonergic agents for treating sexual dysfunction
US20060223824A1 (en) * 2000-11-28 2006-10-05 Wyeth Serotonergic agents
DK1408976T5 (da) 2001-07-20 2011-01-10 Psychogenics Inc Behandling af ADHD (Attention deficit hyperactivity disorder)
RU2315762C2 (ru) 2002-03-12 2008-01-27 Уайт Способ синтеза хиральных n-арилпиперазинов
BR0308347A (pt) 2002-03-12 2005-01-25 Wyeth Corp Processo para fabricação de piperazinas 1,4-dissubstituìdas quirais
US7091349B2 (en) 2002-03-12 2006-08-15 Wyeth Process for synthesizing N-aryl piperazines with chiral N′-1-[benzoyl(2-pyridyl)amino]-2-propane substitution
US7361773B2 (en) 2002-03-12 2008-04-22 Wyeth Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines
GB0219961D0 (en) * 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US20040192730A1 (en) * 2003-03-13 2004-09-30 Dynogen Pharmaceuticals, Inc. Methods of using compounds with combined 5-HT1A and SSRI activities as-needed to treat sexual dysfunction
US20070099931A1 (en) * 2004-03-19 2007-05-03 Wyeth Pharmaceutical dosage forms and compositions
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
US20050209245A1 (en) * 2004-03-19 2005-09-22 Wyeth Process for preparing N-aryl-piperazine derivatives
KR100646337B1 (ko) * 2004-06-30 2006-11-23 주식회사 롯데기공 보일러의 누수 감지방법
DE602005021534D1 (de) * 2004-10-15 2010-07-08 Us Gov Health & Human Serv Amphipathische helixförmige multidomänenpeptide und verfahren zu deren anwendung
TW200700413A (en) * 2005-03-01 2007-01-01 Wyeth Corp Crystalline and amorphous 4-cyano-n-{(2r)-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin-1-yl]-propyl}-n-pyridin-2-yl-benzamide hydrochloride
TW200800959A (en) * 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
EP1893617A1 (en) * 2005-06-17 2008-03-05 Wyeth a Corporation of the State of Delaware Tricyclic compounds useful as serotonin inhibitors and 5-ht1a agonists and antagonists
EP1993527A4 (en) * 2006-01-26 2009-08-05 Univ Rochester INHIBITION OF AMYLOID BETA PEPTIDE / RAGE INTERACTION AT BLOOD BRAIN BARRIER
TW200808740A (en) * 2006-06-09 2008-02-16 Wyeth Corp Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
TW200811144A (en) * 2006-06-09 2008-03-01 Wyeth Corp Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
TW200808741A (en) * 2006-06-09 2008-02-16 Wyeth Corp 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
CL2007003410A1 (es) * 2006-11-28 2008-04-11 Wyeth Corp Compuestos derivados de 5-fluoro-8-{4-[4-(6-metoxiquinolin-8-il)piperazin-1-il]piperidin-1-il}quinolina; procedimiento de preparacion; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de trast
TW200901974A (en) * 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
WO2009129263A1 (en) * 2008-04-15 2009-10-22 The Government Of The Usa As Represented By The Secretary Of The Department Of Health & Human Serv. Peptides promoting lipid efflux via abca1 and activating a lipoprotein lipase

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL101722A (en) 1991-05-02 1996-05-14 Wyeth John & Brother Ltd History of piperazine, their preparation and pharmaceutical preparations containing them
GB9514901D0 (en) 1995-07-20 1995-09-20 American Home Prod Piperazine derivatives

Also Published As

Publication number Publication date
US6586436B2 (en) 2003-07-01
US6469007B2 (en) 2002-10-22
AU2002237654B2 (en) 2005-07-28
NO20032390L (no) 2003-07-22
DE60103927D1 (de) 2004-07-22
TR200401546T4 (tr) 2004-09-21
US20030022901A1 (en) 2003-01-30
WO2002044142A3 (en) 2002-08-08
JP4198989B2 (ja) 2008-12-17
KR20030051879A (ko) 2003-06-25
HUP0400551A2 (en) 2006-02-28
EP1339406B1 (en) 2004-06-16
WO2002044142A2 (en) 2002-06-06
CA2428039C (en) 2011-08-09
MXPA03004677A (es) 2003-09-05
AU3765402A (en) 2002-06-11
ATE269078T1 (de) 2004-07-15
PL363219A1 (en) 2004-11-15
BR0115609A (pt) 2003-11-11
EP1339406A2 (en) 2003-09-03
US20020107254A1 (en) 2002-08-08
JP2004520289A (ja) 2004-07-08
DE60103927T2 (de) 2005-06-23
US20030216408A1 (en) 2003-11-20
NZ526150A (en) 2004-11-26
NO325501B1 (no) 2008-05-26
KR100835552B1 (ko) 2008-06-09
US7026320B2 (en) 2006-04-11
CN1477961A (zh) 2004-02-25
DK1339406T3 (da) 2004-09-27
PT1339406E (pt) 2004-10-29
TWI224102B (en) 2004-11-21
CN100352437C (zh) 2007-12-05
EA200300619A1 (ru) 2003-10-30
NO20032390D0 (no) 2003-05-27
ES2222401T3 (es) 2005-02-01
EA005925B1 (ru) 2005-08-25
AR035603A1 (es) 2004-06-16
IL156098A0 (en) 2003-12-23
CA2428039A1 (en) 2002-06-06

Similar Documents

Publication Publication Date Title
HK1057864A1 (en) Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders.
EP1434801A4 (en) TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM
MXPA02008801A (es) Derivados de indol, proceso para la preparacion de los mismos y su uso.
AU2002212226A1 (en) Use of indole derivatives for treating illnesses of the central nervous system
AU9112201A (en) Pulmonary delivery in treating disorders of the central nervous system
ZA200300411B (en) Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders.
HK1047871A1 (en) Apparatus and methods for making multiple, complexly patterned extrudates.
MXPA02007232A (es) Derivados aminados de dihidro-1,3,5-triazina y sus ojos terapeuticos.
MXPA03000873A (es) Derivados de quinazolina, medicamentos que contienen estos compuestos, su uso y metodos para la produccion de los mismos.
SI0908458T1 (sl) Substituirani piridilmetilpiperazinovi in piperidinovi derivati, njihova priprava in njihova uporaba za zdravljenje motenj centralnega zivcnega sistema (cns)
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
HUP0303568A3 (en) Benzothiophene derivatives, process for their preparation and use thereof
MXPA03000574A (es) Vidrios ceramizados, proceso para su preparacion y uso.
HUP0302295A3 (en) Thienodibenzoazulene derivatives, process for their preparation and use thereof
GC0000155A (en) 6-Hydroxy-indazole derivatives for treating glaucoma.
HK1041880A1 (en) Compounds and methods for treatment of asthma, allergy and inflammatory disorders.
MXPA03006607A (es) Metodo combinado para tratar trastornos dependientes de hormonas.
ZA200205098B (en) Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders.
MXPA03006249A (es) Derivados de 2-arilimino-2,3-dihidrotiazoles, sus procesos de preparacion y su uso terapeutico.
MXPA03004190A (es) Tratamiento de trastornos de ansiedad.
MXPA02012894A (es) Catecoles nitrados substituidos, su uso en el tratamiento de algunos trastornos del sistema nervioso central y periferico y composiciones farmaceuticas que los contienen.
WO2001007431A3 (en) Benzothiophene derivatives
MXPA03001472A (es) Compuestos para el tratamiento de trastornos adictivos.
SI1339406T1 (en) Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders
MXPA03004849A (es) Coniosetina y sus derivados, metodo para producirla y su uso.

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20091127